Cargando…
Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
PsA is a complex, heterogeneous disease that can place a large burden on patients’ psychological and physical well-being. The multifaceted nature of PsA poses a significant assessment challenge, both in randomized control trials and in clinical practice. In recent years, there has been much progress...
Autores principales: | McGagh, Dylan, Coates, Laura C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065465/ https://www.ncbi.nlm.nih.gov/pubmed/32159792 http://dx.doi.org/10.1093/rheumatology/kez305 |
Ejemplares similares
-
Treat-to-target in PsA: methods and necessity
por: Dures, Emma, et al.
Publicado: (2020) -
Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA
por: Frasca, Loredana, et al.
Publicado: (2018) -
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023) -
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022) -
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021)